keyword
MENU ▼
Read by QxMD icon Read
search

adherence treatment schizophrenia

keyword
https://www.readbyqxmd.com/read/28449560/assessment-of-the-latent-adverse-events-of-antipsychotic-treatment-using-a-subjective-questionnaire-in-japanese-patients-with-schizophrenia
#1
Masakazu Hatano, Hiroyuki Kamei, Azusa Kato, Ippei Takeuchi, Manako Hanya, Junji Uno, Shigeki Yamada, Kiyoshi Fujita, Nakao Iwata
Objective: The adverse effects of antipsychotic agents can have a marked influence on medication adherence. In this study, we. investigated the adverse events of antipsychotics that are less likely to be reported by patients and the reasons why such symptoms remain latent. Methods: Data were collected by interviewing patients using a subjective questionnaire, and the associations between unreported symptoms and background factors were investigated. Results: A total of 306 patients with schizophrenia or schizoaffective disorder were examined...
May 31, 2017: Clinical Psychopharmacology and Neuroscience: the Official Scientific Journal of the Korean College of Neuropsychopharmacology
https://www.readbyqxmd.com/read/28395674/antipsychotic-treatment-resistance-in-first-episode-psychosis-prevalence-subtypes-and-predictors
#2
A Demjaha, J M Lappin, D Stahl, M X Patel, J H MacCabe, O D Howes, M Heslin, U A Reininghaus, K Donoghue, B Lomas, M Charalambides, A Onyejiaka, P Fearon, P Jones, G Doody, C Morgan, P Dazzan, R M Murray
BACKGROUND: We examined longitudinally the course and predictors of treatment resistance in a large cohort of first-episode psychosis (FEP) patients from initiation of antipsychotic treatment. We hypothesized that antipsychotic treatment resistance is: (a) present at illness onset; and (b) differentially associated with clinical and demographic factors. METHOD: The study sample comprised 323 FEP patients who were studied at first contact and at 10-year follow-up...
April 11, 2017: Psychological Medicine
https://www.readbyqxmd.com/read/28382557/long-acting-injectable-antipsychotics-in-schizophrenia-literature-review-and-practical-perspective-with-a-focus-on-aripiprazole-once-monthly
#3
REVIEW
Enrico Biagi, Enrico Capuzzi, Fabrizia Colmegna, Alessandra Mascarini, Giulia Brambilla, Alessandra Ornaghi, Jacopo Santambrogio, Massimo Clerici
INTRODUCTION: Prevention of relapse is a major challenge in schizophrenia, a disease characterized by poor adherence to antipsychotic medication leading to multiple rehospitalizations and a substantial burden-of-care. METHODS: We narratively review published clinical data from the development of long-acting injectable (LAI) formulations of antipsychotic drugs and examine the comparative effectiveness of oral versus LAIs in schizophrenia, with a focus on the second-generation LAI antipsychotic aripiprazole...
April 5, 2017: Advances in Therapy
https://www.readbyqxmd.com/read/28374699/-comparative-evaluation-of-clinical-and-economic-efficiency-of-paliperidone-in-various-dosage-forms-used-in-patients-with-schizophrenia
#4
I N D'yakov, S K Zyryanov
AIM: To evaluate clinical and economic efficacy of schizophrenia treatment with three forms of paliperidone (peroral form, intramuscular injections once a month and once in three month). MATERIAL AND METHODS: Pharmacoeconomic analysis based on the results of earlier foreign randomized clinical studies on paliperidone in treatment of schizophrenia was carried out. Indirect comparison of different medication forms of paliperidone compared to placebo was performed...
2017: Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova
https://www.readbyqxmd.com/read/28356723/treatment-patterns-in-medicaid-patients-with-schizophrenia-initiated-on-a-first-or-second-generation-long-acting-injectable-versus-oral-antipsychotic
#5
Dominic Pilon, Kruti Joshi, Neeta Tandon, Marie-Hélène Lafeuille, Rhiannon L Kamstra, Bruno Emond, Patrick Lefebvre
BACKGROUND: Poor antipsychotic (AP) adherence is a key issue in patients with schizophrenia. First-generation antipsychotic (FGA) and second-generation antipsychotic (SGA) long-acting injectable therapies (LAI) may improve adherence compared to oral antipsychotics (OAP). The objective of the study was to compare treatment adherence and persistence in Medicaid patients with schizophrenia initiated on first-generation long-acting injectable therapies (FGA-LAI) or second-generation long-acting injectable therapies (SGA-LAI) versus OAP...
2017: Patient Preference and Adherence
https://www.readbyqxmd.com/read/28344764/atypical-antipsychotics-recent-research-findings-and-applications-to-clinical-practice-proceedings-of-a-symposium-presented-at-the-29th-annual-european-college-of-neuropsychopharmacology-congress-19-september-2016-vienna-austria
#6
REVIEW
Robin Murray, Christoph U Correll, Gavin P Reynolds, David Taylor
Available evidence suggests that second-generation atypical antipsychotics are broadly similar to first-generation agents in terms of their efficacy, but may have a more favourable tolerability profile, primarily by being less likely to cause extrapyramidal symptoms. However, atypical antipsychotics are variably associated with disturbances in the cardiometabolic arena, including increased body weight and the development of metabolic syndrome, which may reflect differences in their receptor binding profiles...
March 2017: Therapeutic Advances in Psychopharmacology
https://www.readbyqxmd.com/read/28342943/would-i-take-antipsychotics-if-i-had-psychotic-symptoms-examining-determinants-of-the-decision-to-take-antipsychotics
#7
Fabrice Berna, Anja S Göritz, Pierre-Michel Llorca, Pierre Vidailhet, Guillaume Fond, Steffen Moritz
Poor adherence to treatment in schizophrenia is mainly associated to patients-related factors. However, social negative representations of schizophrenia and its treatment may also contribute to patients' decision to take or not to take antipsychotics. A web-based study on 1,807 participants was conducted during which participants imagined that they had a particular chronic illness based on clinical vignettes (mental illnesses: schizophrenia, depression; somatic illnesses: multiple sclerosis, rheumatoid arthritis)...
March 22, 2017: Progress in Neuro-psychopharmacology & Biological Psychiatry
https://www.readbyqxmd.com/read/28325572/lipid-profile-disturbances-in-antipsychotic-naive-patients-with-first-episode-non-affective-psychosis-a-systematic-review-and-meta-analysis
#8
REVIEW
Błażej Misiak, Bartłomiej Stańczykiewicz, Łukasz Łaczmański, Dorota Frydecka
BACKGROUND: Dyslipidaemia is one of the most prevalent metabolic disturbances observed in schizophrenia patients and has been largely attributed to the effects of poor lifestyle habits and adverse effects of antipsychotic treatment. However, less is known whether patients with first-episode non-affective psychosis (FENP) present subthreshold indices of dyslipidaemia. Therefore, we tested the hypothesis whether subclinical lipid profile alterations occur already in antipsychotic-naïve FENP patients...
March 18, 2017: Schizophrenia Research
https://www.readbyqxmd.com/read/28287773/alcohol-use-and-service-utilization-among-veterans-in-treatment-for-schizophrenia
#9
Eric R Pedersen, Wenjing Huang, Amy N Cohen, Alexander S Young
Comorbid alcohol and drug use disorders are treatable and have substantial effects on outcomes and health care utilization in people with schizophrenia. While these substance use disorders (SUDs) are thought to be common in patients with schizophrenia, it has been difficult to characterize prevalence and treatment utilization of this population, since administrative data and medical records may not identify patients with schizophrenia who have an SUD diagnosis. In this study, we used an in-person, population-based survey of 801 individuals with schizophrenia who were in treatment within the Veterans Health Administration (VHA) to inform service delivery for patients with these problems...
March 13, 2017: Psychological Services
https://www.readbyqxmd.com/read/28267822/occlusal-dysesthesia-a-clinical-report-on-the-psychosomatic-management-of-a-japanese-patient-cohort
#10
Hitoshi Oguchi, Yu Yamauchi, Yasuyo Karube, Nobue Suzuki, Katsushi Tamaki
PURPOSE: A cohort of Japanese patients diagnosed with occlusal dysesthesia (OD) was clinically analyzed for psychosomatic background, management, and treatment outcome. MATERIALS AND METHODS: The study group comprised 61 patients (17 men and 44 women) who met the OD criteria. Treatment outcomes were categorized as improvement, interruption, and transfer to another department. RESULTS: The diagnosed OD was resolved in 25 patients (41%), 20 patients (33%) discontinued treatment, 13 (21%) were referred or transferred to other specialties such as psychiatry, and 3 (5%) continued to receive treatment following an engagement period of 3 months, 2 years, and 5 years, respectively...
March 2017: International Journal of Prosthodontics
https://www.readbyqxmd.com/read/28258047/mobile-phone-apps-for-smoking-cessation-quality-and-usability-among-smokers-with-psychosis
#11
Joelle C Ferron, Mary F Brunette, Pamela Geiger, Lisa A Marsch, Anna M Adachi-Mejia, Stephen J Bartels
BACKGROUND: Smoking is one of the top preventable causes of mortality in people with psychotic disorders such as schizophrenia. Cessation treatment improves abstinence outcomes, but access is a barrier. Mobile phone apps are one way to increase access to cessation treatment; however, whether they are usable by people with psychotic disorders, who often have special learning needs, is not known. OBJECTIVE: Researchers reviewed 100 randomly selected apps for smoking cessation to rate them based on US guidelines for nicotine addiction treatment and to categorize them based on app functions...
March 3, 2017: JMIR Human Factors
https://www.readbyqxmd.com/read/28236956/financial-incentives-for-improving-adherence-to-maintenance-treatment-in-patients-with-psychotic-disorders-money-for-medication-a-multicentre-open-label-randomised-controlled-trial
#12
Ernst L Noordraven, André I Wierdsma, Peter Blanken, Anthony F T Bloemendaal, Anton B P Staring, Cornelis L Mulder
BACKGROUND: Provision of financial incentives is a promising intervention for improving adherence in patients taking antipsychotic medication. We aimed to assess the effectiveness of this intervention for improving adherence to antipsychotic depot medication in patients with psychotic disorders, irrespective of their previous compliance. METHODS: We did this multicentre, open-label, randomised controlled trial at three mental health-care institutions in secondary psychiatric care services in the Netherlands...
March 2017: Lancet Psychiatry
https://www.readbyqxmd.com/read/28195931/should-antipsychotic-medications-for-schizophrenia-be-given-for-a-lifetime-a-naturalistic-long-term-follow-up-study
#13
Ira D Glick, John M Davis, Daisy Zamora, Jacob Ballon, Meena Nuthi
BACKGROUND: Schizophrenia remains a major health problem despite antipsychotic medications that, for most patients, can decrease acute symptoms, decrease relapses, and contribute to partial and sometimes strong positive response in patients with chronic symptoms. What has not been clear-because a double-blind, randomized, placebo-controlled trial is not feasible or ethical-is how many years after the initial episode, or onset of antipsychotic treatment, should medication be continued to achieve the best global outcome...
April 2017: Journal of Clinical Psychopharmacology
https://www.readbyqxmd.com/read/28184317/adherence-to-medication-in-the-community-audit-cycle-of-interventions-to-improve-the-assessment-of-adherence
#14
REVIEW
Saeed Farooq, Abid Choudry
Aims and method To investigate whether medication adherence is monitored during follow-up in out-patient reviews. A retrospective audit was carried out with a sample of 50 follow-up patients with a diagnosis of schizophrenia or schizoaffective disorder. Following this, interventions were made prior to the re-audit (including text messaging clinicians and prompt sheets in the out-patient department to encourage adherence discussions). Results There was an improvement on all the standards set for this audit following the interventions...
February 2017: BJPsych Bulletin
https://www.readbyqxmd.com/read/28181959/indications-for-and-use-of-long-acting-injectable-antipsychotics-consideration-from-an-inpatient-setting
#15
Taishiro Kishimoto, Sohag Sanghani, Mark J Russ, Akeem N Marsh, Joshua Morris, Suparna Basu, Majnu John, John M Kane
Studies have examined the differences in sociodemographic/clinical characteristics between patients on long-acting injectable (LAI) versus oral medications. However, most studies did not focus specifically on patients for whom LAIs would clearly be indicated. We performed a chart review of patients with schizophrenia or schizoaffective disorder. Patients were categorized as having an 'indication for an LAI' or not on the basis of their adherence history. Patients for whom an LAI was indicated and prescribed on discharge were then compared with similar patients for whom an LAI was not prescribed...
February 8, 2017: International Clinical Psychopharmacology
https://www.readbyqxmd.com/read/28170299/gender-dysphoria-and-co-existing-psychosis-review-and-four-case-examples-of-successful-gender-affirmative-treatment
#16
Julia H Meijer, Guus M Eeckhout, Roy H T van Vlerken, Annelou L C de Vries
PURPOSE: Controversy exists as to if, and when, gender affirmative (GA) treatment should be offered to individuals with gender dysphoria (GD) and co-existing psychosis. Concerns exist regarding a high risk of misdiagnosis, regret afterward due to impulsive decision making, and deterioration of psychotic symptoms. This case series aims at extending the sparse literature on GA treatment in this population by identifying challenges in diagnosis and treatment and offering recommendations to overcome them...
April 2017: LGBT Health
https://www.readbyqxmd.com/read/28150091/reliability-and-validity-of-the-short-version-of-udvalg-for-kliniske-undersogelser-in-antipsychotic-treatment
#17
Kun-Po Chen, For-Wey Lung
The aim of this study was to develop a reliable and valid short version of the Udvalg for Kliniske Undersogelser (UKU) to efficiently evaluate the side effects of antipsychotics in patients with schizophrenia. This multi-site study included 10 hospitals, which included 331 inpatients and outpatients diagnosed with schizophrenia. UKU, Clinical Global Impression-Severity (CGI-S), Personal and Social Performance (PSP) and dosage of paliperidone were collected. The predictive validity of the UKU-short version, as well as that of the CGI-S, PSP and paliperidone dosages, was analyzed using structural equation modeling (SEM), latent growth models (LGM), and confirmatory factor analysis to test its content and construct validity...
February 1, 2017: Psychiatric Quarterly
https://www.readbyqxmd.com/read/28133766/exposure-response-analysis-after-subcutaneous-administration-of-rbp-7000-a-once-a-month-long-acting-atrigel-formulation-of-risperidone
#18
Vijay Ivaturi, Mathangi Gopalakrishnan, Jogarao V S Gobburu, Weiyan Zhang, Yongzhen Liu, Christian Heidbreder, Celine M Laffont
AIMS: A new, long-acting, subcutaneous (SC) formulation of risperidone (RBP-7000) has been developed for the treatment of schizophrenia to address issues of non-adherence associated with oral risperidone treatment. The objective of this work was to establish an exposure-response relationship between total active moiety (AM) plasma exposure (risperidone + 9-hydroxy-risperidone) and Positive and Negative Syndrome Scale (PANSS) or Clinical Global Impression severity (CGI-S) scores using data from a registration trial...
January 30, 2017: British Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/28128334/protein-kinase-c-%C3%AE-a-new-target-therapy-to-prevent-the-long-term-atypical-antipsychotics-induced-weight-gain
#19
Alessandro Rimessi, Chiara Pavan, Elli Ioannidi, Federica Nigro, Claudia Morganti, Alberto Brugnoli, Francesco Longo, Chiara Gardin, Letizia Ferroni, Michele Morari, Vincenzo Vindigni, Barbara Zavan, Paolo Pinton
Antipsychotic drugs are currently used in clinical practice for a variety of mental disorders. Among them, clozapine is the most effective medication for treatment-resistant schizophrenia and is most helpful in controlling aggression and the suicidal behavior in schizophrenia and schizoaffective disorder. Although clozapine is associated with a low likelihood of extrapyramidal symptoms and other neurological side effects, it is well-known for the weight gain and metabolic side effects, which expose the patient to a greater risk of cardiovascular disorders, premature death, as well as psychosocial issues leading to non-adherence to therapy...
January 27, 2017: Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology
https://www.readbyqxmd.com/read/28119036/one-year-mirror-image-study-using-paliperidone-palmitate-for-relapse-prevention-of-schizophrenia-in-four-university-hospitals-in-canada
#20
Philippe D Vincent, Marie-France Demers, Venessa Doyon-Kemp, Josée Duchesneau, Alex Halme, Violaine Masson
BACKGROUND: Superiority of long acting injectable antipsychotics (LAI) over oral antipsychotics remains controversial and dependent on study design and inclusion criteria. Meta-analysis of 21 RCTs demonstrated no difference in their effectiveness, but meta-analysis of 25 mirror-image studies did. None of these included paliperidone palmitate (PP). METHODS: We challenged efficiency of PP in a multicentric mirror-image study. Primary outcome was total hospitalization days...
January 21, 2017: Schizophrenia Research
keyword
keyword
110266
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"